Affiliation:
1. Laboratory of Immunopharmacology and Experimental Therapeutics, Division of Cancer Research, Regional Cancer
Centre, Thiruvananthapuram, 695011, Kerala, India
Abstract
Abstract:
Mucositis is a debilitating and severe side effect of chemotherapy and radiotherapy. It is
responsible for reducing the patient's quality of life and represents a significant economic burden
in oncology. Currently, there is no definitive and definite treatment for this disease. Intracellular
signalling pathways have provided excellent drug development resources, particularly cancer therapeutic
development. In recent decades, active research has been conducted to describe the pathogenesis
of mucositis and the role of nuclear factor-kappa B (NF-κB) signalling pathways in mucositis
development. Insights into the mechanisms of mucositis are creating new approaches for
effective targeted treatment and their success in clinical use. Several studies have concentrated on
elucidating the functional significance of NF-kB activation and its signalling mechanisms in mucositis
in recent decades. Also, evidence indicates that NF-κB is the primary node for the development
and progression of mucositis. Its altered expression is associated with increased mucosal
injury in mucositis. Hence, regulating the activation of NF-κB could be a powerful strategy for the
clinical management of mucositis. Thus, this review examines the role of NF-κB as a potential
therapeutic target for chemotherapy and radiation-induced mucositis therapy.
Funder
Department of Biotechnology, Government of India
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biotechnology